Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2026 13:30 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis

Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials
March 18, 2026 08:00 ET | Source: Alumis Inc.

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 American Academy of Dermatology Annual Meeting

Alumis Announces Late-Breaker Oral Presentation of Phase 3 Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis at 2026 AAD Meeting
February 24, 2026 07:03 ET | Source: Research and Markets

Inflammatory Bowel Disease Treatment Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Launches, Sustainability Goals, Revenue Insights

Dublin, Feb. 24, 2026 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights,...
January 16, 2026 04:56 ET | Source: Research and Markets

Actionable Insights in the Dermatology Market: Navigating Technological Advances and Growth Trends

Dublin, Jan. 16, 2026 (GLOBE NEWSWIRE) -- The "Dermatology Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering. The dermatology market is undergoing a...
January 09, 2026 16:05 ET | Source: Alumis Inc.

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 07, 2026 22:52 ET | Source: Alumis Inc.

Alumis Announces Pricing of Upsized Public Offering of Common Stock

Alumis Announces Pricing of Upsized Public Offering of Common Stock
January 06, 2026 16:12 ET | Source: Alumis Inc.

Alumis Announces Proposed Public Offering of Common Stock

Alumis Announces Proposed Public Offering of Common Stock
January 06, 2026 07:00 ET | Source: Alumis Inc.

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program

Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program
January 05, 2026 17:00 ET | Source: Alumis Inc.

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis

Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
December 19, 2025 09:14 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor

Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 The decision is supported by the...